Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Butler, Timothy M ^a   Johnson Camacho, Katherine ^a   Peto, Myron ^a   Wang, Nicholas J ^a   Macey, Tara A ^a   Korkola, James E ^a   Koppie, Theresa M ^a   Corless, Christopher L ^a   Gray, Joe W ^a   Spellman, Paul T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CASE REPORT; CELL HETEROGENEITY; DNA SEQUENCE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESR1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EXOME; FEASIBILITY STUDY; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MASTECTOMY; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; OVARIECTOMY; PIK3CA GENE; Q546R GENE; R88Q GENE; SARCOMA; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; BLOOD; GENETICS; METASTASIS; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY;

AMINO ACID SUBSTITUTION; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; EXOME; FEMALE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; SARCOMA;

EID: 84943328606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136407     Document Type: Article

References (36)

1. Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, et al. National Cancer Institue.
2. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Seminars in cancer biology. 2012;22(3):234-49. doi: 10.1016/j.semcancer.2012.03.006 PMID: 22484561.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012;366(10):883-92. doi: 10.1056/NEJMoa1113205 PMID: 22397650.
4. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. The New England journal of medicine. 2013;368(9):842-51. doi: 10.1056/NEJMra1 204892 PMID: 23445095.
5. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-40. doi: 10. 1038/nature11219 PMID: 22722843; PubMed Central PMCID: PMC3436069.
6. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNAin early- and late-stage human malignancies. Science translational medicine. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094 PMID: 24553385.
7. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532-6. doi: 10.1038/nature11156 PMID: 22722830; PubMed Central PMCID: PMC3927413.
8. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nature reviews Cancer. 2011;11(6):426-37. doi: 10.1038/nrc3066 PMID: 21562580.
9. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994;3(1):67-71. PMID: 8118388.
10. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast cancer research and treatment. 2010;120(2):461-7. doi: 10.1007/s10549-010-0747-9 PMID: 20107891.
11. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clinical chemistry. 2013;59(1):211-24. doi: 10.1373/clinchem.2012.196014 PMID: 23065472.
12. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(45):16368-73. doi: 10.1073/pnas.0507904102 PMID: 16258065; PubMed Central PMCID: PMC1283450.
13. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Science translational medicine. 2012;4(136):136ra68. doi: 10.1126/scitranslmed.3003726 PMID: 22649089.
14. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. British Journal of Haematology. 1994;86(4):774-9. doi: 10.1111/j.1365-2141.1994.tb04828.x PMID: 7918071
15. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. The New England journal of medicine. 2013;368(13):1199-209. doi: 10.1056/NEJMoa1213261 PMID: 23484797.
16. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nature medicine. 2008;14(9):985-90. doi: 10.1038/nm.1789 PMID: 18670422; PubMed Central PMCID: PMC2820391.
17. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science translational medicine. 2012;4(162):162ra54. doi: 10.1126/scitranslmed.3004742 PMID: 23197571.
18. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancertherapy by sequencing of plasma DNA. Nature. 2013;497(7447):108-12. doi: 10.1038/nature12065 PMID: 23563269.
19. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine. 2014. doi: 10.1038/nm.3519 PMID: 24705333.
20. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Science translational medicine. 2010;2(20):20ra14. doi: 10.1126/scitranslmed.3000702 PMID: 20371490; PubMed Central PMCID: PMC2858564.
21. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Science translational medicine. 2014;6(224):224ra26. doi: 10.1126/scitranslmed.3007947 PMID: 24553387.
22. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. Journal of thoracic oncology: official publication of the International Association forthe Study of Lung Cancer. 2012;7(9):1369-81. doi: 10.1097/JTO.0b013e31825f2821 PMID: 22858585.
23. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(24):7808-15. doi: 10.1158/1078-0432. CCR-11-1712 PMID: 21976538.
24. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007;13(7):2068-74. doi: 10. 1158/1078-0432. CCR-06-2120 PMID: 17404088; PubMed Central PMCID: PMC2720029.
25. Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. American journal of obstetrics and gynecology. 2005;193(3 Pt 1):662-7. doi: 10.1016/j.ajog.2005.01.054 PMID: 16150257.
26. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews Clinical oncology. 2013;10(8):472-84. doi: 10.1038/nrclinonc.2013.110 PMID: 23836314.
27. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochimicaetbiophysicaacta. 2007;1775(1):181-232. doi: 10.1016/j.bbcan. 2006.10.001 PMID: 17137717.
28. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer letters. 2008;263(2):170-81. doi: 10.1016/j.canlet.2008.03.021 PMID: 18395974.
29. Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. The Journal of molecular diagnostics: JMD. 2011;13(5):504-13. doi: 10.1016/j.jmoldx.2011.04.003 PMID: 21726664; PubMed Central PMCID: PMC3157616.
30. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormoneresistant metastatic breast cancer. Nature genetics. 2013;45(12):1446-51. doi: 10.1038/ng.2823 PMID: 24185510.
31. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013;45(12):1439-45. doi: 10.1038/ng.2822 PMID: 24185512; PubMed Central PMCID: PMC3903423.
32. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheelertransform. Bioinformatics. 2009;25(14):1754-60. doi: 10.1093/bioinformatics/btp324 PMID: 19451168; PubMed Central PMCID: PMC2705234.
33. http://picard.sourceforge.net/.
34. De Pristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics. 2011;43(5):491-8. doi: 10.1038/ng.806 PMID: 21478889; PubMed Central PMCID: PMC3083463.
35. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research. 2010;20(9):1297-303. doi: 10.1101/gr.107524.110 PMID: 20644199; PubMed Central PMCID: PMC2928508.
36. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology. 2013;31(3):213-9. doi: 10.1038/nbt.2514 PMID: 23396013; PubMed Central PMCID: PMC3833702.